Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labeled heparin fragment

Cytometry

Volumn 23, Issue 1, 1996, Pages 59-66

  Harenberg, J ^a   Maisch, R ^a   Piazolo, L ^a   Huhle, G ^a   Heene, D L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cellular binding; flow cytometry; granulocytes; heparin; lymphocytes; monocytes

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL;

BINDING SITES; BINDING, COMPETITIVE; CELL MEMBRANE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GRANULOCYTES; HEPARIN; HUMANS; LEUKOCYTES; LYMPHOCYTES; MOLECULAR WEIGHT; MONOCYTES; OLIGOSACCHARIDES; PEPTIDE FRAGMENTS;

EID: 0030022721     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19960101)23:1<59::AID-CYTO9>3.0.CO;2-H     Document Type: Article

References (18)

1. Barzu T, van Rijn JLML, Petitou M, Molho P, Tobelem G, Caen JP: Endothelial binding sites for heparin. Specificity and role in heparin neutralization. Biochem J 238:847-854, 1986.
2. Bleiberg I, MacGregor I, Aronson M: Heparin receptors on mouse macrophages. Thromb Res 29:53-61, 1983.
3. Castellot JJ, Beeler DL, Rosenberg RD, Karnovsky MJ: Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 120:315-323, 1984.
4. Glabe CG, Harty PK, Rosen SD: Preparation and properties of fluorescent polysaccharides. Anal Biochem 130:287-294, 1983.
5. Harenberg J: Pharmacology of low molecular weight heparins. Sem Thromb Hemostas 16(Suppl):12-18, 1990.
6. Harenberg J, Maisch R: German patent no. P 42 17 917.3, 1992.
7. Harlan JH: Leukocyte-endothelial interactions. Blood 65:513-524. 1985.
8. Hirsh J: Heparin. N Engl J Med 324:1565-1574, 1991.
9. Jackson RL, Busch SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71:481-539, 1991.
10. Leung L, Saigo K, Grant D: Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood 73:177-184, 1989.
11. Majack RA, Cook SC, Bornstein P: Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci USA 83:9050-9056, 1986.
12. Malsch R, Guerrini M, Torri G, Löhr G, Casu B, HarenbergJ: Synthesis of a N′-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. Anal Biochem 217:255-264, 1994.
13. Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD: Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 261:7507-7586, 1986.
14. Melissari E, Thye C, Scully M, Kakkar VV: Influence of whole blood on standard curve for heparin measurement - possible heparin binding by red cells. Thromb Haemostas 61:262-265, 1989.
15. Ross R: The pathogenesis of atherosclerosis - an update. N Engl J Med 314:488-492, 1986.
16. Stehle G, Friedrich EA, Sinn H, Wunder A, Harenberg J, Dempfle CE, Maier-Borst W, Heene DL: Hepatic uptake of a modified low molecular weight heparin in rats. J Clin Invest 90:2110-2116, 1992.
17. Stehle G, Sinn H, Friedrich EA, Wunder A, Schrenk HH, Harenberg J, Peschke P, Dempfle CE, Maier-Borst W, Heene DL: Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. J Lab Clin Med 122:728-738, 1993.
18. Yoffe JR, Taylor DJ, Woolley DE: Mast-cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte/macrophages. Biochem J 230:83-89, 1985.